A cost-efficacy analysis of subcutaneous anti-tumor necrosis factor therapy in the treatment of psoriatic arthritis

被引：0
|
作者：
Tandon, N. [1 ]
Kavanaugh, A. [2 ]
Han, C. [3 ]
机构：
[1] Centocor Ortho Biotech Serv LLC, Horsham, PA USA
[2] Univ Calif San Diego, La Jolla, CA 92093 USA
[3] Johnson & Johnson Pharmaceut Serv LLC, Malvern, PA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2012年 / 66卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB6 / AB6
页数：1
相关论文
共 50 条
  • [1] Anti-tumor necrosis factor α therapy in psoriatic arthritis and psoriasis
    Girolomoni, G
    Abeni, D
    ARCHIVES OF DERMATOLOGY, 2001, 137 (06) : 784 - 785
  • [2] The comparative effectiveness of methotrexate and anti-tumor necrosis factor therapy in psoriatic arthritis
    Christopher T. Ritchlin
    Current Rheumatology Reports, 2008, 10 (4) : 295 - 296
  • [3] Minimal Disease Activity and Anti-Tumor Necrosis Factor Therapy in Psoriatic Arthritis
    Haddad, Amir
    Thavaneswaran, Arane
    Ruiz-Arruza, Ioana
    Pellett, Fawnda
    Chandran, Vinod
    Cook, Richard J.
    Gladman, Dafna D.
    ARTHRITIS CARE & RESEARCH, 2015, 67 (06) : 842 - 847
  • [4] Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis
    Kavanaugh, Arthur
    Tutuncu, Zuhre
    Catalan-Sanchez, Teresa
    CURRENT OPINION IN RHEUMATOLOGY, 2006, 18 (04) : 347 - 353
  • [5] Antiangiogenic effects of anti-tumor necrosis factor a therapy with infliximab in psoriatic arthritis
    Cañete, JD
    Pablos, JL
    Sanmartí, R
    Mallofré, C
    Marsal, S
    Maymó, J
    Gratacós, J
    Mezquita, J
    Mezquita, C
    Cid, MC
    ARTHRITIS AND RHEUMATISM, 2004, 50 (05): : 1636 - 1641
  • [6] A cost-efficacy analysis of etanercept and infliximab in the treatment of psoriatic arthritis
    Yu, EB
    Woolley, JM
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 400 - 400
  • [7] Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-α antibody
    Wollina, U
    Konrad, H
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2002, 16 (02) : 127 - 129
  • [8] A COST-EFFICACY ANALYSIS MODEL FOR PHYSICIAN ADMINISTERED ANTI-TUMOR NECROSIS FACTOR AGENTS IN CROHN'S DISEASE
    Waters, H.
    McKenzie, R. S.
    Tang, B.
    Piech, C. T.
    Papandrikopoulou, N.
    VALUE IN HEALTH, 2008, 11 (06) : A521 - A521
  • [9] A cost-efficacy analysis model for physician administered anti-tumor Necrosis factor agents in Crohn's Disease
    Waters, H.
    McKenzie, R.
    Tang, B.
    Piech, C.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S37 - S38
  • [10] A cost-efficacy analysis model for physician administered anti-tumor necrosis factor agents in Crohn's disease
    Waters, H.
    McKenzie, R.
    Tang, B.
    Piech, C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S393 - S393
12345